BVF group sells 1,630,658 Kymera (KYMR) shares in joint Form 4
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Funds affiliated with BVF Partners reported significant stock sales in Kymera Therapeutics, Inc. common shares. On 2026-06-26, Section 13(d) group members filed a joint Form 4 showing open-market sales totaling 1,630,658 shares of Kymera common stock at $106.50 per share, split between direct and indirect holdings.
The filing also lists a series of vested and time-based stock options, with exercise prices ranging from $14.18 to $99.87 per share and expirations from 2030 to 2036, held indirectly through BVF-managed entities. In addition, the group retains several pre-funded warrants exercisable at $0.0001 per share that, according to the disclosure, are exercisable at any time and do not expire. Collectively, these derivatives indicate that BVF-affiliated vehicles remain substantial economic holders of Kymera beyond the reported common share sales.
Positive
- None.
Negative
- None.
Insights
BVF-affiliated funds disclosed a sizable net sale of Kymera shares while retaining large derivative exposure.
The joint Form 4 for Kymera Therapeutics (KYMR) shows BVF-related funds completing open-market sales of 1,630,658 common shares at $106.50 per share on June 26, 2026. The transactions are split between direct and indirect holdings across multiple partnership and fund entities within a Section 13(d) group.
Alongside the sales, the filing lists remaining stock options and pre-funded warrants over hundreds of thousands of underlying shares, with option strike prices from $14.18 to $99.87 and expirations out to 2036. Footnotes clarify layered beneficial ownership and pecuniary-interest arrangements, emphasizing that various BVF vehicles and principals "may be deemed" to beneficially own the securities.
Because the document does not quantify Kymera’s total shares outstanding, the proportion of holdings sold versus retained cannot be inferred here. The combination of a net-sell event with substantial continuing equity and derivative positions suggests portfolio rebalancing or profit-taking rather than a clearly directional change in overall exposure based solely on this disclosure.
Insider Trade Summary
Net Seller: 1,630,658 shares ($173,665,077)
Net Sell
17 txns
Insider
BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N
Role
null | null | null | null | null | null | null | null | null | null
Sold
1,630,658 shs ($173.67M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock, $0.0001 par value | 837,914 | $106.50 | $89.24M |
| Sale | Common Stock, $0.0001 par value | 627,597 | $106.50 | $66.84M |
| Sale | Common Stock, $0.0001 par value | 113,289 | $106.50 | $12.07M |
| Sale | Common Stock, $0.0001 par value | 51,858 | $106.50 | $5.52M |
| holding | Pre-Funded Warrants to Purchase Common Stock | -- | -- | -- |
| holding | Pre-Funded Warrants to Purchase Common Stock | -- | -- | -- |
| holding | Pre-Funded Warrants to Purchase Common Stock | -- | -- | -- |
| holding | Pre-Funded Warrants to Purchase Common Stock | -- | -- | -- |
| holding | Pre-Funded Warrants to Purchase Common Stock | -- | -- | -- |
| holding | Pre-Funded Warrants to Purchase Common Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Common Stock, $0.0001 par value — 1,960,881 shares (Direct, null);
Common Stock, $0.0001 par value — 78,787 shares (Indirect, See footnote);
Pre-Funded Warrants to Purchase Common Stock — 201,546 shares (Direct, null);
Pre-Funded Warrants to Purchase Common Stock — 27,797 shares (Indirect, See footnote);
Stock Option (Right to Buy) — 40,127 shares (Indirect, See footnote)
Footnotes (1)
- This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS. Securities held in a certain Partners managed account (the "Partners Managed Account"). Partners may be deemed to have indirect beneficial ownership of the securities of the Issuer held by the Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10% of the market value of the portfolio of the Partners Managed Account as of the reporting date. Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account. The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire. Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. The shares subject to the option have fully vested. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.
Key Figures
Net common shares sold: 1,630,658 shares
Reported sale price: $106.50 per share
Indirect common shares after sale: 78,787 shares
+5 more
8 metrics
Net common shares sold
1,630,658 shares
Aggregate open-market or private sales reported for 2026-06-26
Reported sale price
$106.50 per share
Price for each Kymera common share sold on 2026-06-26
Indirect common shares after sale
78,787 shares
Indirect holding total following one reported sale row
Direct common shares after sale
1,960,881 shares
Direct holding total following one reported sale row
Largest direct pre-funded warrant position
550,425 underlying shares
Pre-funded warrants exercisable at $0.0001 with no expiration
Highest option exercise price
$99.87 per share
Stock option over 6,068 shares expiring 2036-06-23
Lowest option exercise price
$14.18 per share
Stock option over 12,000 shares expiring 2032-06-14
Sell transactions count
4 sales
Number of S-code open-market sale entries in the filing
Key Terms
Pre-Funded Warrants to Purchase Common Stock, Section 13(d) group, beneficial ownership, pecuniary interest, +1 more
5 terms
Pre-Funded Warrants to Purchase Common Stock financial
"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire."
Section 13(d) group regulatory
"Each of the Reporting Persons is a member of a Section 13(d) group."
beneficial ownership financial
"Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic..."
Stock Option (Right to Buy financial
"Stock Option (Right to Buy) ... The shares subject to the option have fully vested."
FAQ
Do BVF-affiliated holders still retain Kymera (KYMR) common stock after these sales?
Yes. Individual transaction rows show remaining direct and indirect common stock positions after each sale, including 78,787 shares in one indirect account and 1,960,881 shares in one direct account. These figures are per-entity post-transaction holdings and indicate continuing equity exposure to Kymera Therapeutics.
What are the terms of the pre-funded warrants reported for Kymera (KYMR)?
The pre-funded warrants are exercisable into Kymera common stock at an exercise price of $0.0001 per share. Footnote F6 states they are exercisable at any time after issuance, subject to conditions and limitations, and that they do not expire, giving holders enduring low-cost conversion rights.
Who are the reporting persons in this Kymera (KYMR) Form 4 filing?
Reporting persons include multiple BVF entities—such as Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP, BVF Partners L.P., BVF Inc., and Mark N. Lampert. Footnote F1 notes they form a Section 13(d) group and disclaim beneficial ownership beyond pecuniary interests.